Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 315

1.

Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment.

Konya J, Ng JM, Cox H, Cooke M, Lewis N, Bhandari S, Atkin SL, Kilpatrick ES.

Diabet Med. 2013 Oct;30(10):1250-4. doi: 10.1111/dme.12249. Epub 2013 Jul 9.

PMID:
23758176
2.

Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring.

Vos FE, Schollum JB, Coulter CV, Manning PJ, Duffull SB, Walker RJ.

Nephrology (Carlton). 2012 Feb;17(2):182-8. doi: 10.1111/j.1440-1797.2011.01517.x.

PMID:
21883672
3.

The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease.

Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES.

Diabetes Care. 2010 Nov;33(11):2310-3. doi: 10.2337/dc10-0917. Epub 2010 Aug 26.

4.
5.

Reduction in glycated albumin can predict change in HbA1c: comparison of oral hypoglycaemic agent and insulin treatments.

Won HK, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC.

Diabet Med. 2012 Jan;29(1):74-9. doi: 10.1111/j.1464-5491.2011.03386.x.

PMID:
21781151
6.

Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma.

Paroni R, Ceriotti F, Galanello R, Battista Leoni G, Panico A, Scurati E, Paleari R, Chemello L, Quaino V, Scaldaferri L, Lapolla A, Mosca A.

Clin Biochem. 2007 Dec;40(18):1398-405. Epub 2007 Aug 10.

7.

Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection.

Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E, Nishizawa Y; Osaka CKD Expert Research Group.

J Am Soc Nephrol. 2007 Mar;18(3):896-903. Epub 2007 Jan 31.

8.

Glycated albumin in diabetic patients with chronic kidney disease.

Zheng CM, Ma WY, Wu CC, Lu KC.

Clin Chim Acta. 2012 Oct 9;413(19-20):1555-61. doi: 10.1016/j.cca.2012.04.025. Epub 2012 May 10. Review.

PMID:
22579765
10.

Strong correlation between glycaemic variability and total glucose exposure in type 2 diabetes is limited to subjects with satisfactory glycaemic control.

Suh S, Joung JY, Jin SM, Kim MY, Bae JC, Park HD, Lee MS, Lee MK, Kim JH.

Diabetes Metab. 2014 Sep;40(4):272-7. doi: 10.1016/j.diabet.2014.01.006. Epub 2014 Mar 11.

PMID:
24630733
11.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.

PMID:
22078152
12.

No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes.

Godbout A, Hammana I, Potvin S, Mainville D, Rakel A, Berthiaume Y, Chiasson JL, Coderre L, Rabasa-Lhoret R.

Diabetes Metab. 2008 Dec;34(6 Pt 1):568-73. doi: 10.1016/j.diabet.2008.05.010. Epub 2008 Oct 14.

PMID:
18922724
13.

Comparison of cystatin C- and creatinine-based estimation of glomerular filtration rate according to glycaemic status in Type 2 diabetes.

Oh SJ, Lee JI, Ha WC, Jeong SH, Yim HW, Son HS, Sohn TS.

Diabet Med. 2012 Jul;29(7):e121-5. doi: 10.1111/j.1464-5491.2012.03628.x.

PMID:
22414167
14.

Defining the relationship between average glucose and HbA1c in patients with type 2 diabetes and chronic kidney disease.

Lo C, Lui M, Ranasinha S, Teede HJ, Kerr PG, Polkinghorne KR, Nathan DM, Zheng H, Zoungas S.

Diabetes Res Clin Pract. 2014 Apr;104(1):84-91. doi: 10.1016/j.diabres.2014.01.020. Epub 2014 Feb 3.

PMID:
24573088
15.

Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose.

Juraschek SP, Steffes MW, Selvin E.

Clin Chem. 2012 Dec;58(12):1648-55. doi: 10.1373/clinchem.2012.188367. Epub 2012 Sep 27.

16.

Fasting plasma glucose 6-12 weeks after starting insulin glargine predicts likelihood of treatment success: a pooled analysis.

Karl D, Zhou R, Vlajnic A, Riddle M.

Diabet Med. 2012 Jul;29(7):933-6. doi: 10.1111/j.1464-5491.2012.03640.x.

17.

Nontraditional markers of glycemia: associations with microvascular conditions.

Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, Steffes MW.

Diabetes Care. 2011 Apr;34(4):960-7. doi: 10.2337/dc10-1945. Epub 2011 Feb 18.

18.

Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial.

Villar E, Lièvre M, Kessler M, Lemaître V, Alamartine E, Rodier M, François M, Zaoui P, Moranne O, Choukroun G, Guerraoui A, Jolivot A, Janin G, Branger B, Heng AE, Boudray C, Bissery A, Rabilloud M, Pouteil-Noble C.

J Diabetes Complications. 2011 Jul-Aug;25(4):237-43. doi: 10.1016/j.jdiacomp.2011.03.003. Epub 2011 May 20.

PMID:
21601481
19.
20.

Glycated proteins as indices of glycaemic control in diabetic patients with chronic renal failure.

Morgan L, Marenah CB, Jeffcoate WJ, Morgan AG.

Diabet Med. 1996 Jun;13(6):514-9.

PMID:
8799653

Supplemental Content

Support Center